Scigen Limited
ASX:SIE ISIN:AU000000SIE0
SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.
SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market.
SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherlands.
News
Following the Demerger of Dart Energy Limited (ASX:DTE) from Arrow Energy Limited (ASX:AOE) (PINK:ARWEF) and the subsequent establishment of Dart as an independent ASX-listed company, the Board has been seeking to build out the executive and management team of Dart.
SciGen Limited (ASX: SIE) announces that it has been awarded the GMP certification of its manufacturing facility in Rehovot, Israel where its third generation hepatitis B vaccine Sci B Vac is manufactured. This comes after having successfully implemented and complied with all the requirements as specified by the World Health Organisation (WHO) and the Ministry of Health of Israel.
6,978 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 7) (Last 30 Days: 24) (Since Published: 6978)